Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Cash from Operations data on record, last reported at 5108000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 39.26% year-over-year to 5108000.0; the TTM value through Sep 2025 reached 27663000.0, up 29.64%, while the annual FY2024 figure was 35496000.0, 30.72% up from the prior year.
  • Cash from Operations reached 5108000.0 in Q3 2025 per RANI's latest filing, up from 5751000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4048000.0 in Q1 2021 and bottomed at 14629000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 9710526.32, with a median of 9402000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 1759.7% in 2021, then skyrocketed 41.2% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 11449000.0 in 2021, then fell by 27.78% to 14629000.0 in 2022, then increased by 14.7% to 12478000.0 in 2023, then skyrocketed by 30.64% to 8655000.0 in 2024, then surged by 40.98% to 5108000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 5108000.0 in Q3 2025, 5751000.0 in Q2 2025, and 8149000.0 in Q1 2025.